T. Yoshino, R. Obermannova, G. Bodoky, R. Garcia-carbonero, T. Ciuleanu et al., Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial, European Journal of Cancer, vol.78, pp.61-70, 2017.
DOI : 10.1016/j.ejca.2017.03.007

A. Cohn, T. Yoshino, V. Heinemann, R. Obermannova, G. Bodoky et al., Exposure???response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial, Cancer Chemotherapy and Pharmacology, vol.16, issue.5, 2017.
DOI : 10.1208/s12248-014-9631-6

M. Caulet, T. Lecomte, O. Bouche, J. Rollin, V. Gouilleux-gruart et al., Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients, Clinical Pharmacokinetics, vol.108, issue.5, pp.1381-94, 2016.
DOI : 10.1038/bjc.2013.79

N. Azzopardi, T. Lecomte, D. Ternant, M. Boisdron-celle, F. Piller et al., Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients, Clinical Cancer Research, vol.17, issue.19, pp.6329-6366, 2011.
DOI : 10.1158/1078-0432.CCR-11-1081

URL : https://hal.archives-ouvertes.fr/hal-00616314

L. Gibiansky and E. Gibiansky, Target-mediated drug disposition model for drugs that bind to more than one target, Journal of Pharmacokinetics and Pharmacodynamics, vol.63, issue.5, pp.323-369, 2010.
DOI : 10.1007/BF00199290

W. Wang, J. Lin, T. Lin, T. Chiou, J. Liu et al., Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer, International Journal of Colorectal Disease, vol.16, issue.2, pp.96-101, 2001.
DOI : 10.1007/s003840000266

C. Kut, M. Gabhann, F. Popel, and A. , Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer, British Journal of Cancer, vol.53, issue.7, pp.978-85, 2007.
DOI : 10.1016/j.canlet.2003.09.018

T. Solberg, J. Nearman, J. Mullins, S. Li, and J. Baranowska-kortylewicz, Correlation Between Tumor Growth Delay and Expression of Cancer and Host VEGF, VEGFR2, and Osteopontin in Response to Radiotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.72, issue.3, pp.918-944, 2008.
DOI : 10.1016/j.ijrobp.2008.06.1925

M. Waldner, S. Wirtz, A. Jefremow, M. Warntjen, C. Neufert et al., VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer, The Journal of Experimental Medicine, vol.2008, issue.13, pp.2855-68, 2010.
DOI : 10.3748/wjg.14.2662